BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:sonelokimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of sonelokimab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06641089-104@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20270104
DTEND;VALUE=DATE:20270105
SUMMARY:sonelokimab: Phase 3 readout est. (NCT06641089)
DESCRIPTION:sonelokimab\, phase 3\, Psoriatic Arthritis.\nStudy: Evaluation
  of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα
  Inadequate Response\nEstimated primary completion: 4 January 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/sonelokimab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06641089
URL:https://assetmemo.bio/drug/sonelokimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07223138-104@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20280204
DTEND;VALUE=DATE:20280205
SUMMARY:sonelokimab: Phase 3 readout est. (NCT07223138)
DESCRIPTION:sonelokimab\, phase 3\, Psoriatic Arthritis.\nStudy: A Study to
  Evaluate the Long-term Safety\, Tolerability\, and Efficacy of Subcutaneo
 us Sonelokimab in Participants With Psoriatic Arthritis\nEstimated primary
  completion: 4 February 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/sonelokimab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07223138
URL:https://assetmemo.bio/drug/sonelokimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07007637-104@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20280613
DTEND;VALUE=DATE:20280614
SUMMARY:sonelokimab: Phase 3 readout est. (NCT07007637)
DESCRIPTION:sonelokimab\, phase 3\, Hidradenitis Suppurativa.\nStudy: A Stu
 dy to Evaluate the Long-term Safety\, Tolerability\, and Efficacy of Subcu
 taneous Sonelokimab in Participants With Moderate to Severe Hidradenitis S
 uppurativa\nEstimated primary completion: 13 June 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/sonelokimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07007637
URL:https://assetmemo.bio/drug/sonelokimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
